DA Davidson analyst Linda Bolton Weiser keeps a Buy rating and $12.50 price target on WW (WW). The analyst notes that while investors buy Eli Lilly (LLY) or Novo Nordisk (NVO) for exposure to GLP-1 drugs, WW’s strategy is about “winning at care” rather than “winning at scripts”. People will need advice on whether to keep taking the drug after they have hit their goal weight and also what to do with their flabby excess skin once they have lost 100 pounds, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WW:
- Short Report: Bears cut down exposure to crypto names as bitcoin price spikes
- WW International, Inc. to Present at the Morgan Stanley Technology, Media & Telecom Conference
- WW price target lowered to $1.50 from $8 at Barclays
- WW price target lowered to $3 from $9 at UBS
- Oprah Winfrey Exits, WW International Board Downsizing